Treating infants for umbilical granuloma with topical clobetasol propionate cream

A letter from Aydin et al (1) on our recently published study (2), states that topical clobetasol propionate should not be routinely used in infants because of the potential local and systemic side effects. We acknowledge that our study lacks information on potential systemic side effects, such as suppression of the hypothalamic-pituitary-adrenal axis, as we did not investigate this. However, the risk of meaningful systemic side effects may be considered negligible, as only a small amount of cream, of between 2-5 mg per application, was applied to a very small surface area. This article is protected by copyright. All rights reserved.